COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
NEW YORK–(BUSINESS WIRE)–COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care centers and Guardant’s clinicogenomic […]
Study Results from COTA, PreciseDx, and Baptist Health South Florida Confirm Novel AI Test, PreciseBreast is Equivalent to Oncotype DX at Predicting Breast Cancer Recurrence
Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ — COTA Inc., a leader in real-world data (RWD) and analytics for oncology, PreciseDx, an innovator in AI-powered digital pathology focused on oncology diagnostics, and Baptist Health South Florida today announced new study results validating the artificial intelligence […]
COTA and PHI, a subsidiary of Texas Oncology, partner to deliver precision medicine for cancer patients
For over a decade, COTA has been tackling the most complicated cancer data to produce real-world data that can power research that will improve care and expand treatment options for patients. And now, with the integration of AI into our data curation process, we have the potential to do data-assisted clinical research with more speed […]
Breaking through the barriers to expand real-world data use across pharma
Pharma companies are engaged in a never-ending quest to get more effective, safer therapies to patients in a faster and more accessible manner. They are constantly looking for ways to innovate, whether that’s exploring new drug classes for rare diseases or creatively connecting with audiences to enhance equity across communities in need. But there are […]
RWD and GenAI: How technology’s new power couple will revolutionize life sciences
Generative AI (GenAI) is quickly proving itself to be one of the most transformative technologies of our time with its ability to synthesize data and create new content as well as (or sometimes better than) its human creators. But GenAI needs a powerful partner if it’s going to wow users with high-quality, trustworthy, bias-free results: […]
COTA and Hackensack Meridian Health at ASCO 2024
Compared to information from clinical trials, real-world data (RWD) provides oncologists and cancer researchers with data on how diverse groups of patients are treated in current clinical practice. Researchers from Hackensack Meridian Health and COTA teamed up to analyze real-world treatment outcomes for people with multiple myeloma – a type of blood cancer. The findings, […]
How Real-World Data Helps Explore Alternative Dosing for Colorectal, Pancreatic Cancer Therapy
Research from MedStar Georgetown Lombardi Comprehensive Cancer Center and COTA shows the potential of a more patient-friendly dosing regimen for Stage 4 CRC/PC or locally advanced PC.
This collaboration highlights how real-world data can contribute to clinical research and can help answer pressing questions about care already taking place in clinical practice.
Key Takeaways from ASH 2022: Real-World Data Gets Down to Business
The American Society of Hematology’s 2021 annual meeting showed that real-world data is no longer the new kid on the block – it’s an indispensable part of the toolkit for therapeutic development and clinical research. COTA is proud to be a part of the discussion, contributing research this year for chronic lymphocytic leukemia.
Are Pharma Companies Ready to Harness the Promises of Real-World Data?
Partnering with Impatient Health, we take a comprehensive look at the realities of real-world data and the challenges that pharma companies face in leveraging it to gain actionable insight, based on feedback from executives at well-known, major pharma companies.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
